MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A

被引：5
|
作者：
Yap, Timothy A.
Schram, Alison
Lee, Elizabeth K.
Simpkins, Fiona
Weiss, Mia C.
LoRusso, Patricia
Hojgaard, Martin
Carneiro, Benedito A.
Moy, Ryan H.
Garrido-Laguna, Ignacio
Koehler, Maria
Unger, Thaddeus J.
Bacque, Emeline
Aguado-Fraile, Elia
Sethuraman, Sunantha
Dhake, Snehal
Liu, Yajun
Fretland, Adrian J.
Sun, Xizi
Xu, Yi
Hawkey, Nathan
Truong, Jen
Lheureux, Stephanie
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-PR008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR008
引用
收藏
页数：2
相关论文
共 4 条
  • [1] Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring CCNE1 amplification and/or deleterious alterations in FBXW7 or PPP2R1A
    Aguado-Fraile, Elia
    Sethuraman, Sunantha
    Petrone, Adam
    Bacque, Emeline
    Schram, Alison
    Lheureux, Stephanie
    Lee, Elizabeth K.
    Koehler, Maria
    Silverman, Ian M.
    Rimkunas, Victoria
    Yap, Timothy A.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] Individualised schedule optimisation improves rates and severity of anaemia in patients ( pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
    Hojgaard, M.
    Yap, T. A.
    Lee, E. K.
    Weiss, M. C.
    Lheureux, S.
    Simpkins, F.
    LoRusso, P.
    Carneiro, B. A.
    Moy, R. H.
    Aguado-Fraile, E.
    Sethuraman, S.
    Soria-Bretones, I.
    Liu, Y.
    Sun, X.
    Hawkey, N.
    Basciano, P.
    Unger, T. J.
    Bacque, E. S.
    Schram, A.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S23 - S24
  • [3] First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.
    Yap, Timothy A.
    Dumbrava, Ecaterina Elena
    Ahnert, Jordi Rodon
    Hong, David S.
    Pant, Shubham
    Karp, Daniel D.
    Piha-Paul, Sarina Anne Anne
    Subbiah, Vivek
    Tsimberidou, Apostolia Maria
    Fu, Siqing
    Janku, Filip
    Montez, Sandra
    Ahmad-Taha, Majd T.
    Guerrero, Darlene
    Nazarenko, Natalya N.
    Moore, Yan
    Soth, Michael
    Kovacs, Jeff
    Heffernan, Timothy P.
    Jones, Philip
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors
    Yap, Timothy
    Patel, Manish
    Henick, Brian
    Moore, Kathleen
    Leary, Alexandra
    Do, Doreen
    Chapman, Josh
    Zhang, Hui
    Roche, Maria
    Newberry, Kate
    Rinne, Mikael
    Juric, Dejan
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S173 - S173
1